Safety profile of iloperidone in the treatment of schizophrenia

Expert Opinion on Drug Safety

Volumn 13, Issue 2, 2014, Pages 241-246

  Dargani, Navin V ^a   Malhotra, Anil K ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotic; Iloperidone; Safety; Schizophrenia

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HALOPERIDOL; ILOPERIDONE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; SCHIZOPHRENIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; ISOXAZOLES; PIPERIDINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84892733133     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.854770     Document Type: Article

References (29)

1. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision making. Expert Opin Pharmacother 2009;10(12): 1917-28
2. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(Suppl 4): 8-13
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-23
4. Vanda Pharmaceuticals. Fanapt (iloperidone) Tablets Full Prescribing Information. Available from: http://www. pharma.us.novartis.com/product/pi/pdf/ fanapt.pdf [Last accessed 9 September 2013]
5. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmcol 2001;25: 904-14
6. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(3): 553-60
7. Szewczak MR, Corbett R, Rush DK, et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1995;274: 1404-13
8. Bishop JR, Bishop DL. Iloperidone for the treatment of schizophrenia. Drugs Today 2010;46(8): 567-79
9. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
10. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11
11. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
12. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molec Psychiatry 2009;14: 804-19
13. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-19
14. DeHert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder. CNS Drugs 2012;26(9): 733-59
15. Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C-759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010;175: 271-3
16. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;17(8): 760-9
17. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP 3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol 2013;33: 3-10
18. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009;14:1024-31
19. Citrome L. Expert Opin Drug Metab Toxicol 2010;6(12): 1551-64
20. Freeman S. Iloperidone-induced retrograde ejaculation. Int Clin Psychopharmacol 2013;28:156
21. Guanci N, Aggrawal R, Schleifer S. Atypical neuroleptic malignant syndrome associated with iloperidone administration. Psychosomatics 2012;53(6): 603-5
22. Muzyk AJ, Cvelich RG, Kincaid BR, Preud'homme XA. Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes. J Neuropsychiatry Clin Neurosci 2012;24(2):E40-1
23. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother 2007;7: 829-39
24. Kotin J, Wilbert D, Verburg D, Seldinger S. Thioridazine and sexual dysfunction. Am J Psychiatry 1976;133(1): 82-5
25. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-96
26. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158: 1774-82
27. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21: 911-36
28. Nielsen J, Graff C, Kanters JK, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011;25(6): 473-90
29. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012;69(9): 904-12